{"nctId":"NCT00974363","briefTitle":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612","startDateStruct":{"date":"2009-09"},"conditions":["Infections, Meningococcal"],"count":697,"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Procedure: Blood Sampling"]},{"label":"Group B","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Blood Sampling"]}],"interventions":[{"name":"Blood Sampling","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that they and/or their parent(s)/guardian(s) can and will comply with the requirements of the protocol should be enrolled in the study.\n* A male or female having been vaccinated with a meningococcal vaccine in the primary study 109069.\n* Written informed consent obtained from parent(s)/guardian(s) of the subject and written informed assent obtained from the subject if the subject is less than 18 years of age, or written informed consent obtained from the subject if the subject has achieved the 18th birthday.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the subject's first visit.\n* History of meningococcal disease; such cases will be documented.\n* Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine since previous vaccination in study 109069.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.\n* Administration of immunoglobulins and/or any blood products within the three months preceding the subject's first visit.\n* Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy\n* Subjects who withdrew consent to be contacted for follow-up studies.","healthyVolunteers":true,"sex":"ALL","minimumAge":"11 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Seroprotected Subjects Against the Vaccine Meningococcal Serogroups","description":"A seroprotected subject was defined as a subject who had anti-meningococcal serogroups A (MenA), C (MenC), W-135 (MenW-135) and Y (MenY) antibody titers equal to or above (≥) the cut-off value of 1:8. The persistence of serum bactericidal antibodies was evaluated using baby rabbit complement (rSBA) titers. The blood analyses were performed at the GSK Biologicals' laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"404","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"404","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"405","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"407","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects Against the Vaccine Meningococcal Serogroups","description":"A seroprotected subject was defined as a subject who had anti-meningococcal serogroups A (MenA), C (MenC), W-135 (MenW-135) and Y (MenY) antibody titers equal to or above (≥) the cut-off value of 1:8. The persistence of serum bactericidal antibodies was evaluated using baby rabbit complement (rSBA) titers. The blood analyses for this timepoint were performed solely at the Public Health of England's (PHE) laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"417","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"409","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"418","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects Against the Vaccine Meningococcal Serogroups","description":"A seroprotected subject was defined as a subject who had anti-meningococcal serogroups A (MenA), C (MenC), W-135 (MenW-135) and Y (MenY) antibody titers equal to or above (≥) the cut-off value of 1:8. The persistence of serum bactericidal antibodies was evaluated using baby rabbit complement (rSBA) titers. The blood analyses for this timepoint were performed solely at the Public Health of England's (PHE) laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"353","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"367","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"301","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"348","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects Against the Vaccine Meningococcal Serogroups","description":"A seroprotected subject was defined as a subject who had anti-meningococcal serogroups A (MenA), C (MenC), W-135 (MenW-135) and Y (MenY) antibody titers equal to or above (≥) the cut-off value of 1:8. The persistence of serum bactericidal antibodies was evaluated using baby rabbit complement (rSBA) titers. The blood analyses for this timepoint were performed solely at the Public Health of England's (PHE) laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"228","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects Against the Vaccine Meningococcal Serogroups","description":"A seropositive subject was defined as a subject who had the anti-meningococcal serogroups A (MenA), C (MenC), W-135 (MenW-135) and Y (MenY) antibody titers equal to or above (≥) the cut-off value of 1:128. The persistence of serum bactericidal antibodies was evaluated using baby rabbit complement (rSBA) titers. The blood analyses were performed at the Public Health of England's (PHE) laboratory and at GSK Biologicals' laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"403","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"398","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"335","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"396","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"380","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"347","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"403","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"407","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"401","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"225","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Titers Against the Vaccine Meningococcal Serogroups","description":"Seropositivity status was defined as the anti-meningococcal serogroups A (MenA), C (MenC), W-135 (MenW-135) and Y (MenY) titers equal to or above the cut-off value of 1:128. Antibody titers were presented as geometric mean titers (GMTs). The blood analyses were performed at the Public Health of England's (PHE) laboratory and at GSK Biologicals' laboratory.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1493.4","spread":null},{"groupId":"OG001","value":"780.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"448.3","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386.9","spread":null},{"groupId":"OG001","value":"174.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"643.8","spread":null},{"groupId":"OG001","value":"296","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1137.5","spread":null},{"groupId":"OG001","value":"1543","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"371.4","spread":null},{"groupId":"OG001","value":"389.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"378.5","spread":null},{"groupId":"OG001","value":"364","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"248.6","spread":null},{"groupId":"OG001","value":"366.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1977.6","spread":null},{"groupId":"OG001","value":"418.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"209.8","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"436.9","spread":null},{"groupId":"OG001","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3502.5","spread":null},{"groupId":"OG001","value":"1028.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"740.5","spread":null},{"groupId":"OG001","value":"69.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"533.4","spread":null},{"groupId":"OG001","value":"49.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1000.2","spread":null},{"groupId":"OG001","value":"124.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibody Concentrations Against the Vaccine Polysaccharides","description":"Antibody concentrations against polysaccharide A (anti-PSA), polysaccharide C (anti-PSC), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY) assessed were equal to or above (≥) the cut-off values of 0.3 micrograms/milliliter (µg/mL ) and 2.0 micrograms/milliliter (µg/mL). Concentration of antibodies was determined by enzyme-linked immunosorbent assay (ELISA).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against the Vaccine Polysaccharides","description":"Antibody concentrations against polysaccharide A (anti-PSA), polysaccharide C (anti-PSC), polysaccharide W-135 (anti-PSW-135) and polysaccharide Y (anti-PSY) assessed were equal to or above (≥) the cut-off values of 0.3 micrograms/milliliter (µg/mL ) and 2.0 micrograms/milliliter (µg/mL). Concentration of antibodies was determined by enzyme-linked immunosorbent assay (ELISA).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.16","spread":null},{"groupId":"OG001","value":"18.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":null},{"groupId":"OG001","value":"10.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.29","spread":null},{"groupId":"OG001","value":"5.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.63","spread":null},{"groupId":"OG001","value":"6.99","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":521},"commonTop":[]}}}